national initiative supporting Saudi Arabia’s Vision 2030 healthcare goals. It is one of the largest biobanks in the Kingdom and the first to receive ISO accreditation, ensuring world-class standards. Over 60,000 Saudi participants have contributed biospecimens, clinical data, and genomic information. It can store more than 10 million samples using advanced automated systems. It focuses on major health challenges such as diabetes, cardiovascular diseases, and cancer, enabling research in genetic predispositions, biomarkers, and personalized medicine. It adheres to strict ethical standards, fostering public trust. Cohorts are organized into disease-based, population-based, and project-based groups to support diverse research needs. Collaborating with government, academia, and industry, it drives innovation and biotechnology advancement. Leveraging Saudi Arabia’s high consanguinity, the Biobank identifies loss-of-function alleles, accelerating drug discovery and precision medicines